Amneal Pharmaceuticals (Amneal Pharmaceuticals) Debt-to-Asset : 0.79 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals Debt-to-Asset?

Amneal Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $229 Mil. Amneal Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2,517 Mil. Amneal Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $3,456 Mil. Amneal Pharmaceuticals's debt to asset for the quarter that ended in Mar. 2024 was 0.79.

Amneal Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Amneal Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amneal Pharmaceuticals Debt-to-Asset Chart

Amneal Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.76

0.74

0.73

0.75

0.79

Amneal Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.79	0.77	0.76	0.79	0.79

Competitive Comparison of Amneal Pharmaceuticals's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amneal Pharmaceuticals's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Amneal Pharmaceuticals's Debt-to-Asset falls into.

Amneal Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Amneal Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(227.624	+	2522.899)	/	3472.569
	=	0.79

Amneal Pharmaceuticals's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(228.665	+	2517.164)	/	3456.397
	=	0.79

Amneal Pharmaceuticals (NAS:AMRX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Amneal Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Amneal Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Amneal Pharmaceuticals (Amneal Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (NAS:AMRX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

2DT:Germany

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807

Website

https://www.amneal.com

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies.

Executives

Andrew S Boyer	officer: Exec VP, Comm Optns	C/O WATSON PHARMA INC, 360 MOUNT KEMBLE AVE, MORRISTOWN NJ 07960
Tpg Gp A, Llc	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Gustavo Pesquin	officer: See Remarks	4 PARK LANE, MADISON NJ 07940
Deborah M. Autor	director	C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Jason B. Daly	officer: SVP, Chief Legal Officer	400 CROSSING BLVD, 3RD FLOOR, BRIDGEWATER NJ 08807
Jon Winkelried	10 percent owner	C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Gautam Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Chirag K. Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Chintu Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER CA 08807
Nikita Shah	officer: SVP, Chief HR Officer	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Joseph Todisco	officer: SVP, Specialty Commercial	400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
John Kiely	director	C/O ZOVIO INC, 1811 E NORTHROP BLVD, CHANDLER AZ 85286
Jeffrey P. George	director	C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Shlomo Yanai	director	ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Paul M Meister	director	18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862